BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation

NEXT STORY
Global Point of Care/Rapid Diagnostics Market (2020 to 2025) – Increasing Provider Awareness About Novel Technologies Presents Opportunities
PREV STORY
Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

author_avatar
NASDAQ Market News

Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine

author_avatar
NASDAQ Market News

Cellectar Biosciences to Present at the LD Micro Invitational Conference

MADISON, Wis., May 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology ...

author_avatar
NASDAQ Market News